Based on the results of the present study in obese individuals with T2DM and other studies in lean to obese subjects without diabetes, it transpires that the onset of action of the rapid-acting insulin analogues is not delayed in obese subjects when using a specific injection site [8]. This evidence concerns the gene INS and type 2 diabetes mellitus.